8-K
false 0001645460 0001645460 2020-09-17 2020-09-17

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 17, 2020

 

 

Cue Biopharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38327   47-3324577

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

21 Erie St., Cambridge, Massachusetts   02139
(Address of principal executive offices)   (Zip Code)

(Registrant’s telephone number, including area code): (617) 949-2680

N/A

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   CUE   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 17, 2020, Tamar Howson was appointed to the board of directors (the “Board”) of Cue Biopharma, Inc. (the “Company”).

There are no arrangements or understandings between Ms. Howson and any other persons pursuant to which Ms. Howson was selected as a member of the Board, and there are no transactions between Ms. Howson and the Company that would be reportable under Item 404(a) of Regulation S-K.

Ms. Howson will receive compensation for her service as a member of the Board in accordance with the Company’s Director Compensation Policy (the “Director Compensation Policy”). In accordance with the terms of the Director Compensation Policy, upon her appointment, Ms. Howson was granted options to purchase 50,000 shares of the Company’s common stock. The options will vest in eight equal semi-annual installments.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Cue Biopharma, Inc.
Date: September 17, 2020     By:  

/s/ Daniel R. Passeri

    Name:   Daniel R. Passeri
    Title:   Chief Executive Officer
 v3.20.2
Document and Entity Information
Sep. 17, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001645460
Document Type 8-K
Document Period End Date Sep. 17, 2020
Entity Registrant Name Cue Biopharma, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38327
Entity Tax Identification Number 47-3324577
Entity Address, Address Line One 21 Erie St.
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code (617)
Local Phone Number 949-2680
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol CUE
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true